Jesus' Coming Back

Israel signs $237mn contract with Pfizer for 8 million doses of Covid vaccine

Israel has signed a formal agreement of intent with US pharma giant Pfizer for some eight million doses of its coronavirus vaccine candidate – if and when it is approved and the company starts supplying it to foreign customers.

Pfizer could receive a front payment of over $35 million as early as next week, even though the agreement does not include any commitment to actually supply the vaccine, Ynet reports. The remaining $200+ million will be paid once some 8 million jabs are shipped, but if the increased demand in the US or other ‘circumstances’ prevent Pfizer from fulfilling the order, Tel Aviv expects a refund.

Also on rt.com Plans on ice: Freezers & logistics are the reasons Pfizer’s vaccine is all hype, and won’t be a magic bullet

Prime Minister Benjamin Netanyahu praised the Israeli Health Ministry, Pfizer and its CEO Albert Bourla personally for his relentless work to seal the deal, marking a “great day for the State of Israel and a great day on the way to our victory over the coronavirus.”

Our national mission is to enable a vaccine for every person in Israel, whoever wants one – without exception.

Netanyahu added that he was in talks with other countries and world leaders too, “to ensure that we will receive the vaccine together with the leading countries around the world and that we will not get pushed back in line.”

READ MORE: Israeli hospital chief rejects Western concerns over Russia’s Sputnik-V Covid-19 vaccine as ‘political,’ orders 1.5 million doses

In the meantime, he urged Israelis to show some patience and obey the government’s anti-Covid directives and rules, acknowledging that “months will pass until the vaccines arrive, assuming that they will be approved.”

Also on rt.com With Sputnik V, Russia takes on Western Big Pharma giants in fight for multi-billion-dollar global Covid-19 vaccine business

Think your friends would be interested? Share this story!

Source

Comments are closed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More